JPH0381227A - Superoxide remover - Google Patents
Superoxide removerInfo
- Publication number
- JPH0381227A JPH0381227A JP1214241A JP21424189A JPH0381227A JP H0381227 A JPH0381227 A JP H0381227A JP 1214241 A JP1214241 A JP 1214241A JP 21424189 A JP21424189 A JP 21424189A JP H0381227 A JPH0381227 A JP H0381227A
- Authority
- JP
- Japan
- Prior art keywords
- superoxide
- extract
- remover
- solution
- extracted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 title claims abstract description 40
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 15
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 13
- 239000000203 mixture Substances 0.000 claims abstract description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000002904 solvent Substances 0.000 claims abstract description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims abstract description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims abstract description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims abstract description 8
- 238000000605 extraction Methods 0.000 claims abstract description 8
- DKPFZGUDAPQIHT-UHFFFAOYSA-N butyl acetate Chemical compound CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000003960 organic solvent Substances 0.000 claims abstract description 5
- 239000002516 radical scavenger Substances 0.000 claims description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 9
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 229940010454 licorice Drugs 0.000 claims description 9
- YKYONYBAUNKHLG-UHFFFAOYSA-N propyl acetate Chemical compound CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 claims description 4
- GJRQTCIYDGXPES-UHFFFAOYSA-N iso-butyl acetate Natural products CC(C)COC(C)=O GJRQTCIYDGXPES-UHFFFAOYSA-N 0.000 claims description 2
- FGKJLKRYENPLQH-UHFFFAOYSA-M isocaproate Chemical compound CC(C)CCC([O-])=O FGKJLKRYENPLQH-UHFFFAOYSA-M 0.000 claims description 2
- OQAGVSWESNCJJT-UHFFFAOYSA-N isovaleric acid methyl ester Natural products COC(=O)CC(C)C OQAGVSWESNCJJT-UHFFFAOYSA-N 0.000 claims description 2
- 241000202807 Glycyrrhiza Species 0.000 claims 2
- 239000000284 extract Substances 0.000 abstract description 16
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 9
- 239000002537 cosmetic Substances 0.000 abstract description 7
- 235000013305 food Nutrition 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 6
- 239000004378 Glycyrrhizin Substances 0.000 abstract description 5
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 abstract description 5
- 229960004949 glycyrrhizic acid Drugs 0.000 abstract description 5
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 abstract description 5
- 235000019410 glycyrrhizin Nutrition 0.000 abstract description 5
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract description 5
- 238000010438 heat treatment Methods 0.000 abstract description 3
- 239000007788 liquid Substances 0.000 abstract description 2
- 238000000746 purification Methods 0.000 abstract description 2
- 230000009967 tasteless effect Effects 0.000 abstract description 2
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical group ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 abstract 1
- 238000010348 incorporation Methods 0.000 abstract 1
- 230000000717 retained effect Effects 0.000 abstract 1
- UBOXGVDOUJQMTN-UHFFFAOYSA-N trichloroethylene Natural products ClCC(Cl)Cl UBOXGVDOUJQMTN-UHFFFAOYSA-N 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 17
- 230000002000 scavenging effect Effects 0.000 description 9
- 102000019197 Superoxide Dismutase Human genes 0.000 description 7
- 108010012715 Superoxide dismutase Proteins 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108010093894 Xanthine oxidase Proteins 0.000 description 3
- 102100033220 Xanthine oxidase Human genes 0.000 description 3
- 229940069445 licorice extract Drugs 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 229940075420 xanthine Drugs 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 206010040954 Skin wrinkling Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000026062 Tissue disease Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- NIFIFKQPDTWWGU-UHFFFAOYSA-N pyrite Chemical compound [Fe+2].[S-][S-] NIFIFKQPDTWWGU-UHFFFAOYSA-N 0.000 description 1
- 229910052683 pyrite Inorganic materials 0.000 description 1
- 239000011028 pyrite Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Landscapes
- General Preparation And Processing Of Foods (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は、医薬、食品、化粧品等の分野で使用可能な、
スーパーオキサイド消去剤に関するものである。[Detailed description of the invention] [Industrial application field] The present invention can be used in the fields of medicine, food, cosmetics, etc.
This invention relates to a superoxide scavenger.
スーパーオキサイドすなわち酸素分子の一電子還元で生
じるラジカル02−は、生体内において重要な防御因子
として作用することが知られている。たとえば、細菌、
ウィルス、異物等が生体内に侵入すると好中球、単球、
マクロファージなどの食細胞が活性化して遊走能や食作
用という動的な機能が発現し、その結果ライ。Superoxide, ie, the radical 02- generated by one-electron reduction of oxygen molecules, is known to act as an important defense factor in living organisms. For example, bacteria,
When viruses, foreign substances, etc. enter the body, neutrophils, monocytes,
Phagocytic cells such as macrophages are activated and express dynamic functions such as migratory ability and phagocytosis, resulting in leprosy.
ソゾーム酵素やスーパーオキサイドが産出されて分泌さ
れるが、これらは貧食物の融解および殺菌に直接または
間接に関与し、身体を外敵から守る。Sosomal enzymes and superoxide are produced and secreted, and these are directly or indirectly involved in the melting and sterilization of poor food, and protect the body from foreign invaders.
その反面、スーパーオキサイドは、生体内に過剰に存在
すると様々な組織障害をもたらす。通常、生体内で生成
するスーパーオキサイドは、呼吸で吸収される酸素の約
1%以下であり、これが細胞内に含まれているスーパー
オキサイドジスムターゼ(SOD)の触媒作用により逐
次消去されているが、老人の身体のように酵素作用が低
下している場合においては消去が不十分になってスーパ
ーオキサイド濃度が高くなり、これが関節リュウマチや
ベーチェット病などの組織障害や、スーパーオキサイド
またはそれにより生成する過酸化脂質が原因の心筋梗塞
、脳卒中、白内障、シミ、ソバカス、しわ、糖尿病、動
脈硬化、肩凝り、冷え性などを起こす。老人でなくても
、皮膚は紫外線など環境因子の刺激を直接受けるためス
ーパーオキサイドが特に生威し易い器官であるから、ス
ーパーオキサイド濃度の上昇とそれにともなう過酸化脂
質の生成が起こり易く、それが原因のメラニン色素の生
成、シミ、小シワ等の障害を起こし易い。On the other hand, superoxide causes various tissue damage when present in excess in a living body. Normally, superoxide produced in living organisms accounts for less than 1% of the oxygen absorbed through respiration, and this is gradually eliminated by the catalytic action of superoxide dismutase (SOD) contained within cells. In cases where enzyme activity is reduced, such as in the body of the elderly, superoxide concentration becomes high due to insufficient scavenging, which can lead to tissue disorders such as rheumatoid arthritis and Behcet's disease, as well as superoxide and the excess produced by it. Oxidized lipids can cause myocardial infarction, stroke, cataracts, age spots, freckles, wrinkles, diabetes, arteriosclerosis, stiff shoulders, and sensitivity to cold. Even if you are not an elderly person, the skin is an organ where superoxide is particularly susceptible to the growth of superoxide as it is directly stimulated by environmental factors such as ultraviolet rays. It is easy to cause problems such as melanin pigment production, age spots, and small wrinkles.
過剰のスーパーオキサイドによる上述のような各種障害
を予防または治療するため、スーパーオキサイドジスム
ターゼを医薬品としたり化粧品や食品に添加したりして
利用する試みは、この酵素が熱に不安定で失活しやすい
ため、また著しく高価であるため、成功していない。Attempts to use superoxide dismutase as a medicine or as an additive to cosmetics or food to prevent or treat the various disorders mentioned above due to excess superoxide have been unsuccessful because this enzyme is unstable and inactivated by heat. It has not been successful because it is easy to use and is extremely expensive.
スーパーオキサイド消去作用を有する物質をスーパーオ
キサイドジスムターゼ以外に求める試みは特開昭64−
50877号公報に記載されており、そこでは、黄芥中
のパイ力レインが利用されている。しかしながら、パイ
力レインは黄芥中に僅かしか含まれておらず、これを抽
出してもきわめて高価なものとなってしまう。An attempt to find a substance other than superoxide dismutase that has a superoxide scavenging effect was made in JP-A-64-
It is described in Japanese Patent No. 50877, in which the pyrite rain in yellow waste is utilized. However, only a small amount of pyriterein is contained in yolk, and even if it is extracted, it is extremely expensive.
本発明の目的は、スーパーオキサイドジスムターゼのよ
うに不安定でなく、医薬品、化粧品、食品等に容易に配
合可能な、安定でしかも安価に入手できる物質からなる
スーパーオキサイド消去剤を提供することにある。An object of the present invention is to provide a superoxide scavenger made of a stable and inexpensively available substance that is not unstable like superoxide dismutase and can be easily incorporated into pharmaceuticals, cosmetics, foods, etc. .
本発明が提供することに成功したスーパーオキサイド消
去剤は、中間極性を有する有機溶媒またはこれと低級ア
ルコールとの混合物を抽出溶媒として甘草または甘草の
水抽出残渣から抽出される成分を含有することを特徴と
するものである。The superoxide scavenger successfully provided by the present invention contains a component extracted from licorice or a water-extracted residue of licorice using an organic solvent having intermediate polarity or a mixture of this and a lower alcohol as an extraction solvent. This is a characteristic feature.
本発明のスーパーオキサイド消去剤は
0、−+ 2 H+→Hzoz+o*
の反応によりスーパーオキサイドを消去するものと考え
られるが、甘草抽出物中のいかなる成分がスーパーオキ
サイドを消去するのかはまだ解明されていない。The superoxide scavenger of the present invention is thought to scavenge superoxide through the reaction 0, -+ 2 H+→Hzoz+o*, but it has not yet been elucidated what component in the licorice extract scavenges superoxide. do not have.
甘草は、それから水抽出により抽出されるグリチルリチ
ンが医薬、甘味料等に古くから利用されているが、本発
明のスーパーオキサイド消去剤の有効成分は甘草の非水
溶性成分中にあるので、原料としては甘草の根部や茎部
だけでなく、それらから水抽出によりグリチルリチンを
抽出した後の残渣も利用することができる。Glycyrrhizin, which is extracted from licorice by water extraction, has been used for medicines, sweeteners, etc. for a long time, but since the active ingredient of the superoxide scavenger of the present invention is in the water-insoluble components of licorice, it can be used as a raw material. It is possible to use not only the licorice roots and stems, but also the residue after glycyrrhizin is extracted from them by water extraction.
甘草からスーパーオキサイド消去剤の有効成分を抽出す
るために使用することのできる中間極性の有機溶媒の例
としては、ベンゼン、エチルエーテル、クロロホルム、
酢酸n−ブチル、酢酸イソブチル、酢酸n−プロピル、
酢酸エチル、塩化メチレン、トリクレン、パークレン等
があり、また、これらと併用することのできる低級アル
コールの例としてはメタノールおよびエタノールがある
。低級アルコールを併用する場合において、その混合率
は約lO〜50vo1%が適当であって、これ以上低級
アルコールの混合比率がふえるとスーパーオキサイド消
去作用を有する成分の抽出効率が低下する。Examples of intermediate polar organic solvents that can be used to extract the active ingredients of superoxide scavengers from licorice include benzene, ethyl ether, chloroform,
n-butyl acetate, isobutyl acetate, n-propyl acetate,
Examples of such alcohols include ethyl acetate, methylene chloride, trichlene, and percrene, and examples of lower alcohols that can be used in combination with these include methanol and ethanol. When a lower alcohol is used in combination, the appropriate mixing ratio is about 10 to 50vol%; if the mixing ratio of the lower alcohol is increased beyond this, the extraction efficiency of the component having a superoxide scavenging effect will decrease.
上述のような抽出溶媒を用いることを除けば、抽出条件
に特殊なものは不要である。標準的な抽出条件を示すと
、被処理原料を3倍程度の抽出溶媒に常温で浸漬して可
溶性成分を溶出させ、適当時間後に固液分離を行う。こ
れらの操作を2〜3回繰り返し、得られた抽出液を合わ
せて濾過し、溶媒を留去すれば、無味で褐色の抽出物が
得られる。この抽出物は、多くの場合、そのまま本発明
のスーパーオキサイド消去剤に使用することができるが
、必要に応じて、その効力を損なわない範囲で脱色等の
精製処理を施してもよい。No special extraction conditions are required except for the use of an extraction solvent as described above. Standard extraction conditions include immersing the raw material to be treated in about 3 times as much extraction solvent at room temperature to elute soluble components, and after an appropriate period of time, performing solid-liquid separation. These operations are repeated 2 to 3 times, the resulting extracts are combined, filtered, and the solvent is distilled off to obtain a tasteless, brown extract. In many cases, this extract can be used as it is in the superoxide scavenger of the present invention, but if necessary, it may be subjected to purification treatments such as decolorization to the extent that its efficacy is not impaired.
得られた甘草抽出物またはその精製物は、そのまま、あ
るいは適当な油脂、1.3−ブチレングリコール、プロ
ピレングリコール、グリセリンモノステアレート等の媒
体に溶解させて、本発明のスーパーオキサイド消去剤と
することができる。また、エタノール等に溶解させてか
ら、ツイーン20.サポニン等の可溶化剤をあらかじめ
溶解した水に添加撹拌すれば、澄明な可溶化状態のもの
とすることができる。The obtained licorice extract or its purified product is used as the superoxide scavenger of the present invention, either as it is or dissolved in a medium such as an appropriate oil or fat, 1,3-butylene glycol, propylene glycol, or glycerin monostearate. be able to. Also, after dissolving in ethanol etc., Tween 20. If a solubilizing agent such as saponin is added to water in advance and stirred, a clear solubilized state can be obtained.
本発明のスーパーオキサイド消去剤の毒性をLitcb
field Wilcoxon法により、ICR系マウ
スを用い、腹腔内投与により調べたところ、LD、。値
は1.9 g/kg以上であった。The toxicity of the superoxide scavenger of the present invention is determined by Litcb.
LD was investigated by intraperitoneal administration using ICR mice according to the field Wilcoxon method. The value was 1.9 g/kg or more.
本発明のスーパーオキサイド消去剤は、医薬品として使
用するほか、化粧品(医薬部外品を含む)、食品等に配
合するなど、広範囲の利用が可能である。化粧品等に配
合する場合、本発明のスーパーオキサイド消去剤の好適
添加量は、甘草抽出物として0.0001〜1.0%程
度である。The superoxide scavenger of the present invention can be used in a wide range of applications, such as being used as a medicine, as well as being incorporated into cosmetics (including quasi-drugs), foods, and the like. When incorporated into cosmetics, etc., the preferred amount of the superoxide scavenger of the present invention is about 0.0001 to 1.0% as a licorice extract.
上述のように本発明のスーパーオキサイド消去剤は甘草
を原料にして容易に製造することができるので安価であ
り、また広いpH範囲で安定したスーパーオキサイド消
去作用を示し、その作用は加熱によっても損なわれない
から、過剰のスーパーオキサイドに起因する前述の疾患
の予防ないし治療のための医薬品として使用するほか、
食品、化粧品等に添加して健康増進と美容のために役立
たせることも可能な、きわめて有用なものである。As mentioned above, the superoxide scavenger of the present invention can be easily produced using licorice as a raw material and is therefore inexpensive, and also exhibits a stable superoxide scavenging effect over a wide pH range, and its effect is impaired even by heating. Therefore, in addition to being used as a medicine for the prevention or treatment of the above-mentioned diseases caused by excessive superoxide,
It is extremely useful and can be added to foods, cosmetics, etc. for health promotion and beauty.
製造実施例1
酢酸エチル10誌にせ草根粉砕物2 kgを常温で5時
間浸漬して酢酸エチル可溶成分を抽出した後、濾過して
抽出液を分離した。同様の操作をさらに2回繰り返し、
抽出液合計2611を得た。抽出液の溶媒を留去し、残
った固形物を減圧下に乾燥し、粉砕して、淡褐色の粉末
72gを得た(これを製剤Aとする)。Production Example 1 2 kg of ground grass roots were soaked in ethyl acetate for 5 hours at room temperature to extract the ethyl acetate soluble components, and then filtered to separate the extract. Repeat the same operation two more times,
A total of 2611 extracts were obtained. The solvent of the extract was distilled off, and the remaining solid was dried under reduced pressure and ground to obtain 72 g of a light brown powder (this is referred to as Formulation A).
製造実施例2
甘草1 kgを1%アンモニア水1(lに浸漬してグリ
チルリチンを抽出した。残渣を乾燥後、3αのエチルエ
ーテルとともに2時間、還流下に加熱し、エチルエーテ
ル可溶成分を抽出した。抽出液と分離した残渣について
再び同様の操作を繰り返し、合計5.5aの抽出液を得
た。この後、抽出液から溶媒を留去し、さらに減圧下に
乾燥して、褐色の粉末25gを得た(これを製剤Bとす
る)。Production Example 2 Glycyrrhizin was extracted by soaking 1 kg of licorice in 1 (l) of 1% aqueous ammonia. After drying the residue, it was heated under reflux with 3α ethyl ether for 2 hours to extract the ethyl ether soluble components. The same operation was repeated again for the extract and the separated residue to obtain a total of 5.5a of extract.Then, the solvent was distilled off from the extract and further dried under reduced pressure to obtain a brown powder. 25 g was obtained (this is designated as formulation B).
製造実施例3
せ草根I Mを温水10Qに浸漬してグリチルリチンを
抽出した。残渣を乾燥し、これをクロロホルム/メタノ
ール混合溶媒(混合比9 : 1) 3rbとともに2
時間、還流下に加熱し、溶媒可溶成分を抽出した。抽出
液と分離した残渣について再び同様の操作を繰り返して
、合計5.51の抽出液を得た。この後、抽出液の溶媒
を留去し、さらに減圧乾燥して、褐色の粉末30gを得
た(これを製剤Cとする)。Production Example 3 Glycyrrhizin was extracted by immersing Sesame root IM in 10Q of warm water. The residue was dried and mixed with 3rb of chloroform/methanol mixed solvent (mixing ratio 9:1).
The mixture was heated under reflux for an hour to extract the solvent-soluble components. The same operation was repeated for the residue separated from the extract to obtain a total of 5.51 extracts. Thereafter, the solvent of the extract was distilled off, and the extract was further dried under reduced pressure to obtain 30 g of brown powder (this is referred to as Formulation C).
試験例1
上記各製造例で得られた製剤について、下記NBT法で
スーパーオキサイド消去作用を調べた。Test Example 1 The preparations obtained in each of the above production examples were examined for superoxide scavenging activity using the NBT method described below.
(1)試薬
■0.O5M N i2c Os緩衝液(pH10,2
)■3mMキサンチン溶液:キサンチン45.64mg
を■の緩衝液に溶解して1011!I+とする。(1) Reagent ■0. O5M N i2c Os buffer (pH 10,2
)■3mM xanthine solution: xanthine 45.64mg
Dissolve it in the buffer solution of ■ and get 1011! Let it be I+.
■3+oMEDTA溶液: EDTA・2Nx 111
.7mgを蒸留水に溶解してloOmlとする。■3+oMEDTA solution: EDTA・2Nx 111
.. Dissolve 7 mg in distilled water to make loOml.
■BSA溶液: Lbvin serum album
in (Sigma) 15m(を蒸留水に溶解してl
11m1とする。■BSA solution: Lbvin serum album
in (Sigma) 15m (dissolved in distilled water and
The area shall be 11m1.
■0.75@M N B T溶液:
NBTにトロブルーテトラゾリウム) 61.32mg
を蒸留水に溶解して10(1mgとする。■0.75@M NBT solution: NBT and troblue tetrazolium) 61.32mg
Dissolve 10 (1 mg) in distilled water.
■キサンチンオキシダーゼ溶液:キサンチンオキシダー
ゼを蒸留水で希釈し、後記(2)の操作の空試験におけ
る吸光度が0.20−0.Hの範囲に入るようにする。■Xanthine oxidase solution: xanthine oxidase was diluted with distilled water, and the absorbance in a blank test of the procedure (2) below was 0.20-0. Make sure it falls within the range of H.
■6@MCuCI2溶液: CuC1*・2Hz0 1
01Ha+gを蒸留水に溶解して100m1とする。■6@MCuCI2 solution: CuC1*・2Hz0 1
Dissolve 01Ha+g in distilled water to make 100ml.
(2)操作
試験管にN s 1 C03緩衝液2.4mgをとり、
これにキサンチン溶液、EDTA溶液、BSA溶液、N
BT溶液、各L1mlを加える。試料溶液(80%エタ
ノール溶液)0.1mgを加え、25°Cで10分間放
置後、キサンチンオキシダーゼ溶液11.1mgを加え
、手早く撹拌し、25℃でインキュベートする620分
後にCuC1,溶液0.1mgを加えて反応を停止させ
、560 nmで吸光度を測定する。比較のため、スー
パーオキサイドジスムターゼ(CII−2n型SOD、
活性: 3000−4000unit/m(。(2) Take 2.4 mg of N s 1 C03 buffer into a test tube,
To this, xanthine solution, EDTA solution, BSA solution, N
Add 1 ml of each liter of BT solution. Add 0.1 mg of sample solution (80% ethanol solution), leave at 25 °C for 10 minutes, add 11.1 mg of xanthine oxidase solution, stir briefly, and incubate at 25 °C. After 620 minutes, CuC1, solution 0.1 mg The reaction is stopped by adding 560 nm, and the absorbance is measured at 560 nm. For comparison, superoxide dismutase (CII-2n type SOD,
Activity: 3000-4000 units/m (.
和光純薬)水溶液0.1mgについても同様の測定を行
う。別に空試験を、試料の代わりに蒸留水を用いて行う
。Similar measurements are made for 0.1 mg of Wako Pure Chemical Industries' aqueous solution. A separate blank test is conducted using distilled water instead of the sample.
測定結果を表1に示す。The measurement results are shown in Table 1.
表1 スーパーオキサイド消去率(%)試験例2
試験例1と同様の試験において、各試料溶液を7000
で10分間加熱したものについてスーパーオキサイド消
去能を測定した。その結果を表2に示す。Table 1 Superoxide elimination rate (%) Test Example 2 In a test similar to Test Example 1, each sample solution was
The superoxide scavenging ability was measured for those heated for 10 minutes. The results are shown in Table 2.
表2 スーパーオキサイド消去率(%、加熱後)試験例
3
製剤Aについて、細胞内におけるスーパーオキサイド消
去能を下記の方法で測定した。Table 2 Superoxide scavenging rate (%, after heating) Test Example 3 The intracellular superoxide scavenging ability of Formulation A was measured by the following method.
培地:イーグルMEMI[(日本製薬)の9.4g/己
を10%NaHCO>溶液を用いて37℃におけるpH
が7.2になるように調製した。本培地は、成苗後24
時間以内に使用した。Medium: pH at 37°C using Eagle MEMI [(Nippon Pharmaceutical) 9.4g/10% NaHCO> solution.
was adjusted so that the value was 7.2. This medium is used for 24 hours after the seedlings have matured.
Used within hours.
多形核白血球の調製:ウィスター系雄性ラットの腹腔内
に流動パラフィン10m1を投与し、12時間後、腹腔
にイーグル培地60m1を注入して腹水80gを採取し
た。採取した腹水を5分間遠心沈殿し、沈渣を1%ラッ
ト血清含有イーグルMEM培地にlXl0’個/mlに
なるよう浮遊させ、PMN標本とした。各実験に際して
、トリバンプルー染色にて生存率を確認した。Preparation of polymorphonuclear leukocytes: 10 ml of liquid paraffin was intraperitoneally administered to male Wistar rats, and 12 hours later, 60 ml of Eagle's medium was injected into the peritoneal cavity to collect 80 g of ascites fluid. The collected ascitic fluid was centrifuged for 5 minutes, and the precipitate was suspended in Eagle's MEM medium containing 1% rat serum at a concentration of 1X10' cells/ml to prepare a PMN specimen. In each experiment, viability was confirmed by Trivan blue staining.
ケミルミネッセンスの測定: PMN浮遊液0.5ml
にルミノール試験液10μmおよび製剤AのDMSO溶
液5μlを加え、37℃で10分間インキュベート後、
2y+sos*nの溶液(0,5mg/ml) 10μ
mを添加し、発生するルミノール依存性ケミルミネッセ
ンスを7オトンカウンターを用いて37℃で測定した。Chemiluminescence measurement: 0.5 ml of PMN suspension
10 μm of luminol test solution and 5 μl of DMSO solution of Formulation A were added to the solution, and after incubation at 37°C for 10 minutes,
2y+sos*n solution (0.5mg/ml) 10μ
m was added, and the luminol-dependent chemiluminescence generated was measured at 37°C using a 7-oton counter.
製剤Aは発光のピークに達する時間をやや遅延させたが
、スーパーオキサイド消去作用は最大発光時におけるカ
ウントを用いて評価した。Formulation A slightly delayed the time to reach the peak luminescence, but the superoxide scavenging effect was evaluated using the count at the time of maximum luminescence.
種々の添加水準におけるスーパーオキサイド消去率測定
結果を表3に示す。製剤Aは、2ymosan刺激によ
り発生したスーパーオキサイドを濃度依存的に強力に捕
捉し、消去した。Table 3 shows the measurement results of superoxide elimination rate at various addition levels. Formulation A strongly captured and eliminated superoxide generated by 2ymosan stimulation in a concentration-dependent manner.
Claims (2)
コールとの混合物を抽出溶媒として甘草または甘草の水
抽出残渣から抽出される成分を含有することを特徴とす
るスーパーオキサイド消去剤。(1) A superoxide scavenger characterized by containing a component extracted from licorice or a water-extracted residue of licorice using an organic solvent having intermediate polarity or a mixture of this and a lower alcohol as an extraction solvent.
ルエーテル、クロロホルム、酢酸n−ブチル、酢酸イソ
ブチル、酢酸n−プロピル、酢酸エチル、塩化メチレン
、トリクレン、またはパークレンを用い、低級アルコー
ルとしてメタノールまたはエタノールを用いて抽出され
た成分を含有する請求項1記載のスーパーオキサイド消
去剤。(2) Use benzene, ethyl ether, chloroform, n-butyl acetate, isobutyl acetate, n-propyl acetate, ethyl acetate, methylene chloride, trichrene, or percrene as an organic solvent with intermediate polarity, and methanol or ethanol as a lower alcohol. The superoxide scavenger according to claim 1, which contains a component extracted using the superoxide scavenger.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP1214241A JPH0381227A (en) | 1989-08-22 | 1989-08-22 | Superoxide remover |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP1214241A JPH0381227A (en) | 1989-08-22 | 1989-08-22 | Superoxide remover |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH0381227A true JPH0381227A (en) | 1991-04-05 |
Family
ID=16652520
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP1214241A Pending JPH0381227A (en) | 1989-08-22 | 1989-08-22 | Superoxide remover |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH0381227A (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001122765A (en) * | 2000-09-28 | 2001-05-08 | Naris Cosmetics Co Ltd | Active oxygen scavenger and cosmetic |
JP2003081744A (en) * | 2001-09-14 | 2003-03-19 | Maruzen Pharmaceut Co Ltd | Antioxidant |
JP2007520548A (en) * | 2004-02-06 | 2007-07-26 | コレア インスティテュート オブ オリエンタル メディスン | Composition for prevention and treatment of diabetic complications |
US8071141B2 (en) | 2000-12-12 | 2011-12-06 | Kaneka Corporation | Compositions for preventing or ameliorating multiple risk factor syndromes |
-
1989
- 1989-08-22 JP JP1214241A patent/JPH0381227A/en active Pending
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001122765A (en) * | 2000-09-28 | 2001-05-08 | Naris Cosmetics Co Ltd | Active oxygen scavenger and cosmetic |
US8071141B2 (en) | 2000-12-12 | 2011-12-06 | Kaneka Corporation | Compositions for preventing or ameliorating multiple risk factor syndromes |
JP2003081744A (en) * | 2001-09-14 | 2003-03-19 | Maruzen Pharmaceut Co Ltd | Antioxidant |
JP2007520548A (en) * | 2004-02-06 | 2007-07-26 | コレア インスティテュート オブ オリエンタル メディスン | Composition for prevention and treatment of diabetic complications |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107674129B (en) | Schizophyllan phosphorylated derivative and preparation method and application thereof | |
JP2903324B2 (en) | Superoxide scavenger | |
KR100982883B1 (en) | Cosmetic composition comprising mixture extract and preparation thereof | |
CN115887518A (en) | Anti-glycation application of sweet wormwood herb extract | |
JPH04342519A (en) | Skin cosmetic | |
EP0973494A1 (en) | Use of an extract of the genus adansonia | |
JP2000044485A (en) | Active oxygen species scavenger and skin cosmetic | |
KR101515073B1 (en) | Trisin inclusion complex, a preparation method thereof, and a cosmetic composition for anti-oxidant and anti-inflammatory comprising the same | |
JP2952636B2 (en) | Melanin production inhibitor, method for producing the same, and whitening cosmetic containing the same | |
JP5196416B2 (en) | Cosmetic composition containing Limnocitrus litoritalis extract | |
JPH0381227A (en) | Superoxide remover | |
JP4768097B2 (en) | Active oxygen scavenger, platelet aggregation inhibitor, skin cosmetic and bath preparation | |
JP5101769B2 (en) | Antibiotic antioxidant or preventive agent | |
JPH0665074A (en) | Active oxygen elimination agent | |
JPH0138762B2 (en) | ||
CN115844939A (en) | Artemisia annua extract with TRPV1 protein inhibiting effect | |
JP2000128729A (en) | Cosmetic | |
JP2003113104A (en) | Expression promoter of uncoupling protein and composition containing the same | |
JP3889894B2 (en) | Antiallergic agents, whitening agents and skin cosmetics | |
JPH03127714A (en) | Skin cosmetic | |
JPH06211679A (en) | Antiinflammatory and antipruritic external preparation | |
JP2000212058A (en) | Skin cosmetic, active oxygen eliminator, esterase inhibitor, and collagenase inhibitor | |
JP2001181129A (en) | Collagenase activity inhibitor | |
KR20100090533A (en) | Method of extracting for sea silt extract and whitening functional cosmetic composition containing the extract | |
Rathod et al. | Antioxidant and Anti-Inflammatory activity in fresh and dry leaves of Ipomoea obscura (L.) ker gawl |